OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET

WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, will hold a conference call on Wednesday, November 11, 2026, at 4:30 p.m.

GlobeNewsWire • Oct 28, 2026

OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel

Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows

GlobeNewsWire • Oct 27, 2026

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).

GlobeNewsWire • Sep 22, 2026

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.

Seeking Alpha • Sep 18, 2026

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow

GlobeNewsWire • Sep 14, 2026

OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced that management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 10, 2026, in New York, NY.

GlobeNewsWire • Sep 8, 2026

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor.

GlobeNewsWire • Sep 2, 2026

OptimizeRx Q2 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

MarketBeat • Aug 13, 2026

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

–  Q2 revenue totals $20.5 million–  Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively–  Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million–  Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception

GlobeNewsWire • Aug 12, 2026